Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial
- 6 June 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 7 (7), 594-604
- https://doi.org/10.1016/s2213-2600(19)30091-8
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2013
- Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertensionEuropean Respiratory Journal, 2012
- Safety and Efficacy of Ambrisentan for the Treatment of Portopulmonary HypertensionSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2011
- Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a Randomized, Placebo-Controlled TrialJournal of the American College of Cardiology, 2008
- Fluid retention in cirrhosis: pathophysiology and managementQJM: An International Journal of Medicine, 2008
- An epidemiological study of pulmonary arterial hypertensionEuropean Respiratory Journal, 2007
- Pulmonary Arterial Hypertension in FranceAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertensionHepatology, 1999
- International Primary Pulmonary Hypertension Study.Heart, 1994